Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto
About this trial
This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients with liver cancer (specifically hepatocellular carcinoma) and who had received a liver transplant as a part of curative care, but the cancer has come back (recurred). The purpose of this study is to see how useful cabozantinib is in controlling the disease of these patients.
Cabozantinib blocks the function of various proteins found on the surface of the body's cells (called receptor tyrosine kinases) that are important in the development of cancer tumors.
All participants will receive cabozantinib until they are no longer receiving benefit from the study drug or they experience an intolerable side effect.
Eligibility criteria
Qualifiers
Have histologically or cytologically confirmed hepatocellular carcinoma that has recurred.
Previously underwent a liver transplant as a curative treatment for hepatocellular carcinoma (HCC).
Not amenable to curative surgery or local treatment for recurrent disease.
Must have measurable disease.
Disqualifiers
Had systemic therapy or radiotherapy <3 weeks.
Receiving any other investigational agents.
With known brain metastases unless stable for >3 months.
History of allergic reactions attributed to cabozantinib.
Trial design
Treatments tested in this trial
- Cabozantinib
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
University Health Network, Toronto
Lead sponsor
Ipsen
Collaborator
Source ClinicalTrials.gov